Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of AZD5363 in Japanese Patients With Advanced Solid Tumours
jRCT2080221764Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of capivasertib in Non-hematologic malignancy and advanced nonhematological malignancy, sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD5363, Pharmacokinetics of AZD5363 and 1 more. Started Apr 2012; status: completed.
02
Drugs
capivasertib
03
Conditions
Non-hematologic malignancyadvanced nonhematological malignancy
Beyond the preview
Go deeper on jRCT2080221764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221764.